13.12 USD
-0.13 (-0.98%)
13.12 USD
0 (0%)
Overall IART gets a fundamental rating of 4 out of 10. We evaluated IART against 188 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
In the past year IART had a positive cash flow from operations.
IART had positive earnings in 4 of the past 5 years.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
IART has a Return On Assets (-13.58%) which is in line with its industry peers.
IART has a Return On Equity (-47.74%) which is comparable to the rest of the industry.
IART's Return On Invested Capital of 4.27% is fine compared to the rest of the industry. IART outperforms 74.47% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a Operating Margin of 10.22%. This is in the better half of the industry: IART outperforms 78.19% of its industry peers.
In the last couple of years the Operating Margin of IART has declined.
IART has a Gross Margin (57.21%) which is in line with its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IART is creating some value.
Compared to 1 year ago, IART has less shares outstanding
The number of shares outstanding for IART has been reduced compared to 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
IART has an Altman-Z score of 1.26. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.26, IART perfoms like the industry average, outperforming 53.19% of the companies in the same industry.
A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
IART's Debt to Equity ratio of 1.73 is on the low side compared to the rest of the industry. IART is outperformed by 80.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.26 |
ROIC/WACC0.74
WACC5.75%
2.3 Liquidity
IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.14, IART is in line with its industry, outperforming 59.57% of the companies in the same industry.
A Quick Ratio of 1.80 indicates that IART should not have too much problems paying its short term obligations.
IART's Quick ratio of 1.80 is in line compared to the rest of the industry. IART outperforms 46.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
The Revenue has been growing slightly by 4.99% in the past year.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.68% yearly.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 2.39% on average per year.
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.54, the valuation of IART can be described as very cheap.
Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 97.87% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.15, IART is valued rather cheaply.
With a Price/Forward Earnings ratio of 5.43, the valuation of IART can be described as very cheap.
IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 98.94% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.12. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.54 | ||
| Fwd PE | 5.43 |
4.2 Price Multiples
95.74% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.12
-0.13 (-0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.73%
Inst Owner Change0%
Ins Owners3.04%
Ins Owner Change0.07%
Market Cap1.02B
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (20.5%)
Short Float %10.31%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)-5.65%
PT rev (3m)-5.65%
EPS NQ rev (1m)-11.49%
EPS NQ rev (3m)-11.49%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-0.6%
Revenue NQ rev (1m)-5.75%
Revenue NQ rev (3m)-5.75%
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-2.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.54 | ||
| Fwd PE | 5.43 | ||
| P/S | 0.62 | ||
| P/FCF | N/A | ||
| P/OCF | 11.45 | ||
| P/B | 0.99 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8 |
EPS(TTM)2.37
EY18.06%
EPS(NY)2.42
Fwd EY18.43%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY8.74%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.26 |
F-Score5
WACC5.75%
ROIC/WACC0.74
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.37%
EPS Next 2Y-2.81%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.34%
Revenue Next 2Y2.11%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.98%
EBIT Next 3Y9.96%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.